1. Home
  2. UVE vs RCUS Comparison

UVE vs RCUS Comparison

Compare UVE & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UVE
  • RCUS
  • Stock Information
  • Founded
  • UVE 1990
  • RCUS 2015
  • Country
  • UVE United States
  • RCUS United States
  • Employees
  • UVE N/A
  • RCUS N/A
  • Industry
  • UVE Property-Casualty Insurers
  • RCUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • UVE Finance
  • RCUS Health Care
  • Exchange
  • UVE Nasdaq
  • RCUS Nasdaq
  • Market Cap
  • UVE 756.8M
  • RCUS 906.4M
  • IPO Year
  • UVE 1992
  • RCUS 2018
  • Fundamental
  • Price
  • UVE $26.99
  • RCUS $8.66
  • Analyst Decision
  • UVE
  • RCUS Buy
  • Analyst Count
  • UVE 0
  • RCUS 10
  • Target Price
  • UVE N/A
  • RCUS $23.75
  • AVG Volume (30 Days)
  • UVE 224.1K
  • RCUS 1.1M
  • Earning Date
  • UVE 07-24-2025
  • RCUS 08-07-2025
  • Dividend Yield
  • UVE 2.87%
  • RCUS N/A
  • EPS Growth
  • UVE N/A
  • RCUS N/A
  • EPS
  • UVE 2.29
  • RCUS N/A
  • Revenue
  • UVE $1,547,444,000.00
  • RCUS $141,000,000.00
  • Revenue This Year
  • UVE N/A
  • RCUS N/A
  • Revenue Next Year
  • UVE $1.13
  • RCUS $28.73
  • P/E Ratio
  • UVE $11.70
  • RCUS N/A
  • Revenue Growth
  • UVE 7.24
  • RCUS N/A
  • 52 Week Low
  • UVE $16.50
  • RCUS $6.50
  • 52 Week High
  • UVE $28.49
  • RCUS $18.98
  • Technical
  • Relative Strength Index (RSI)
  • UVE 56.06
  • RCUS 42.54
  • Support Level
  • UVE $26.74
  • RCUS $8.36
  • Resistance Level
  • UVE $27.73
  • RCUS $8.87
  • Average True Range (ATR)
  • UVE 0.62
  • RCUS 0.48
  • MACD
  • UVE -0.06
  • RCUS -0.12
  • Stochastic Oscillator
  • UVE 65.79
  • RCUS 9.09

About UVE UNIVERSAL INSURANCE HOLDINGS INC

Universal Insurance Holdings Inc is a private personal residential homeowner insurance company. The company develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners' lines of business and performs substantially all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The company generates revenue from the collection of premiums, earned net interest and dividend income from the investment portfolio, the collection of reinsurance recoverable and financing fees. The company's primary insurance subsidiaries, (UPCIC) and (APPCIC) provide insurance for personal residential: homeowners, renters/tenants, condo unit owners, and other related coverages.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: